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PLINICAL RESEARCH Clinical Trials
ffectiveness of Fludrocortisone and
alt in Preventing Syncope Recurrence in Children
Double-Blind, Placebo-Controlled, Randomized Trial
ubadda A. Salim, MD, FACC, Thomas G. Di Sessa, MD, FACC
emphis, Tennessee
OBJECTIVES We sought to evaluate the effectiveness of salt and fludrocortisone versus placebo in the
prevention of syncope recurrence in children.
BACKGROUND Intravascular volume expansion with fludrocortisone and salt has been reported to be effective
in the treatment of syncope in children. However, no pediatric placebo-controlled data are
available on the effectiveness of this mode of therapy.
METHODS Thirty-three children with syncope or severe presyncope were randomized in a double-
blinded fashion to receive either fludrocortisone 0.1 mg/day and salt 1 g/day or placebo two
capsules per day for one year. All children had a positive tilt test before enrollment.
RESULTS Thirty-two children (20 female) had follow-up. Their age was (mean SD) 13.9 2.5 years.
The number of syncopal episodes before therapy was 4.4  4.8. Therapy was continued for
176  117 days, and follow-up including time after discontinuation of medications was
1.2  0.8 years. The demographics were similar in the 18 children treated with fludrocor-
tisone and salt compared with the 14 children on placebo. Data for up to one year of
randomization were included in analyses. Symptoms recurred in 10 of 18 children on
fludrocortisone and salt and in 5 of 14 children on placebo (p  0.04). Children on placebo
had no symptoms until they discontinued their study medications.
CONCLUSIONS These data, coupled with the reported comparable effect of many medications used in the
treatment of syncope, raise the potential of a significant placebo effect with pharmacologic
therapy. (J Am Coll Cardiol 2005;45:484–8) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.033Cardiology Foundation
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teurocardiogenic syncope is a common and recurrent phe-
omenon in children, with a peak incidence in the teenage
ears (1). The diagnosis is established by history, often
onfirmed by tilt testing (2), and therapy is aimed at
reventing or reducing the recurrence of syncope. Initial
eports of effective therapeutic interventions include fludro-
ortisone and salt (3), fludrocortisone alone (4), beta-
drenergic blocking agents (3–5), and pacemakers (6).
owever, all of these studies used an open-label design.
ludrocortisone and salt are commonly used in the treat-
ent of syncope in children. To our knowledge, there are no
ediatric studies that have compared the efficacy of this
ombination with placebo. Thus, we designed a prospective,
andomized, double-blinded, and placebo-controlled study
o compare the effectiveness of fludrocortisone and salt with
lacebo. Our hypothesis was that fludrocortisone and salt
ould be more effective than placebo in the prevention of
yncope recurrence in children.
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eBonheur Children’s Medical Canter, Memphis, Tennessee, and the Pediatric
harmacology Research Unit at the University of Tennessee and LeBonheur
hildren’s Medical Center.i
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004, accepted November 2, 2004.ETHODS
hildren under the age of 18 years were eligible for the
tudy if they presented between December 1995 and January
999. Children with 1 episode of syncope or severe
resyncope were eligible. All children had a normal heart by
xamination, electrocardiography, and echocardiography.
uring the study period, all children underwent an active
ilt test. No drugs were used during the tilt test protocol. No
hild had had any previous therapy for syncope. A positive
ilt test was defined as the induction of symptoms associated
ith a decrease in systolic blood pressure (BP) by more than
0 mm Hg and/or heart rate increase by more 25 beats/min
nd/or significant bradycardia. We utilized a previously
eported active tilt test protocol where the child is asked to
tand for 20 min after 1 h in the supine position (7). The
nstitutional review boards of the University of Tennessee
nd LeBonheur Children’s Medical Center approved our
tudy protocol. An informed parental consent and the
hild’s assent were obtained in every patient.
All patients and parents were educated about the mech-
nisms of syncope and factors that may worsen the child’s
ymptoms. The children were instructed to avoid prolonged
tanding without motion and to avoid stressful situations
hat previously resulted in syncope as well as increase their
ntake of fluids.
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February 15, 2005:484–8 Fludrocortisone and Salt in SyncopeTherapy was limited to one year. Our patients were
andomized to receive either: 1) one fludrocortisone acetate
.1-mg tablet and a sodium chloride (NaCl) 1-g tablet daily,
r 2) two placebo capsules daily. None of the children were
reated previously for syncope; therefore, they were not
ware of the shape and taste of the active drugs. All patients
ere told that the medications given were either meant to
aste salty (in the fludrocortisone and salt group) or that the
edications were coated to avoid detection by their taste
placebo group). Initially, the fludrocortisone acetate (Florinef)
sed in the study was donated by the manufacturer (Apoth-
con, Princeton, New Jersey). After the first year of the
tudy, medications were purchased through an institutional
rant. Children randomized to the treatment arm received
00 tablets of NaCl and 100 tablets of fludrocortisone every
hree months. Those randomized to the placebo group
eceived two forms of placebo tablets or capsules (100 each).
atients were asked to return the unused portion of their
edications as a means to gauge compliance with therapy.
t was assumed that those who did not return any medica-
ion consumed the total number of pills.
Our primary outcome variable was recurrence of syncope.
resyncopal symptoms were not considered failure of ther-
py if they were not associated with frank syncope in
hildren who previously had syncope. However, recurrent
resyncope was considered a failure of therapy in children
ho previously had only presyncope.
Follow-up in the cardiology clinic was at 1, 3, 6, 9, and 12
onths of therapy and 1 to 3 months after therapy was
iscontinued. We asked children and parents to report any
yncopal events during or after therapy. Side effects of
herapy were also assessed during each clinic visit, and a
iary was provided to record any syncopal episodes. For the
hildren who did not return for follow-up visits, data were
btained using a written questionnaire that was mailed to
he last known address and/or a telephone interview. In the
ase of recurrent syncope or intolerable side effects, the
atients were given the option of continuing the same
edications or dropping out of the study and receiving an
pen-label therapy.
tatistical analysis. Two-sample Student t test was used to
ompare means of continuous variables between the two
roups, and the chi-square test was used to assess propor-
ions between the two groups. The probability of being
yncope-free was estimated using the Kaplan-Meier
ethod. Survival curves among groups were compared by
he Wilcoxon test. Intention-to-treat analysis was used. A p
alue0.05 was considered statistically significant. Data are
Abbreviations and Acronyms
BP  blood pressure
NaCl  sodium chlorideisplayed as mean values  1 SD. All analyses were eerformed using SAS version 8 (SAS Institute, Cary, North
arolina).
ESULTS
hirty-three children and parents consented to participate
n the study. There were 20 females; the racial mix was 18
aucasian and 15 African American. The number of
yncopal/presyncopal episodes before tilt testing was 4.4 
.8 (range 1 to 20), and the age at first symptoms was
2.6  3.0 years (range 4.4 to 16.8 years). Their age at the
ime of tilt test was 13.9  2.5 years (range 9.0 to 17.2
ears). The duration of therapy for the entire group was 176
117 days (range 13 to 407 days). Follow-up from the
nitial clinic visit to the last contact with the patients was 1.2
0.8 years (range 0.1 to 5 years). Overall, 18 patients were
andomized to receive salt and fludrocortisone and 15 were
andomized to receive placebo. One of the patients on
lacebo was lost to follow-up after randomization and was
ot included in the analyses.
Overall follow-up was available on 32 of 33 children
97%). There were no significant differences between the
wo treatment groups with regard to: age at first symptoms,
ge at tilt test, number of syncopal episodes before tilt test,
eight, height, male to female ratio, race, duration of
herapy and follow-up, or in the number of pills of either
alt and fludrocortisone or placebo consumed while on the
tudy (Table 1).
Presyncope was the presenting symptom in five children;
our of them were in the salt and fludrocortisone group. The
hildren with presyncope were indistinguishable from those
ith syncope for age at presentation or age at tilt test,
eight, and height from the larger group. Two of the four
hildren with presyncope on salt and fludrocortisone had
ecurrence of their symptoms while on therapy. The one
atient with presyncope on placebo reported no recurrence
f symptoms while on therapy.
The intention was to treat all children for one year.
owever, there was a wide range of treatment duration and
ollow-up. We used a one-year cutoff from the start of
herapy as the time for comparison between the two groups.
f a patient had a follow-up shorter than one year, then the
able 1. Demographics of the Treatment Groups
Salt/
Fludrocortisone Placebo p Value
ge at first symptom (yrs) 12.2  2.9 13.0  3.1 0.4
ge at tilt test (yrs) 13.7  2.7 14.0  2.4 0.7
yncopal episodes 4.1  3.6 5.1  6.0 0.6
eight (kg) 54.3  15.9 52.6  15.1 0.7
eight (cm) 165  16 158  8 0.1
uration of therapy (days) 189  108 159  130 0.4
uration of follow-up (yrs) 1.3  1.1 1.2  0.3 0.5
otal pills consumed 381  209 308  217 0.3
ace (African American/
Caucasian)
7/11 8/6 0.6
ale/female ratio 8/10 4/10 0.3vents during that time were included in the analysis.
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Fludrocortisone and Salt in Syncope February 15, 2005:484–8owever, for patients with a follow-up longer than one
ear, only the events during the first year were considered
or analysis. The Kaplan-Meier curve for symptom-free
urvival is depicted in Figure 1. Symptoms (syncope: 8;
resyncope: 2) were reported in 10 children assigned to the
alt and fludrocortisone group and 5 children (syncope: 4;
resyncope: 1) assigned to the placebo group (p 0.04). All
of the placebo group children reported symptoms only
fter their placebo was discontinued, whereas all 10 of the
alt and fludrocortisone group children who reported symp-
oms did so during active therapy. Symptoms recurred in
wo of the children in the salt and fludrocortisone group
fter therapy was discontinued; both patients had recurrence
hile on therapy.
Side effects on therapy were minimal. No BP abnormal-
ties were noted in either group. One patient on placebo had
iarrhea two weeks into the study, which was attributed to
he treatment, and the patient chose to terminate partici-
ation in the study. Another patient on placebo complained
f headaches. In the group of children on salt and fludro-
ortisone, one complained of palpitations, nausea, dizziness,
hest pain, and another of swelling of his arms and legs.
wo patients also complained of fatigue while on salt and
udrocortisone.
ISCUSSION
his study demonstrates, contrary to our hypothesis, for the
rst time in a randomized, double-blinded, placebo-
ontrolled fashion that 1 g of salt and 0.1 mg of fludrocor-
isone per day plus counseling is ineffective in preventing
yncope or presyncope recurrence in children. Overall, 56%
f the children in the salt and fludrocortisone and counsel-
ng group had recurrence of their symptoms while on
edication. Furthermore, because these results are nearly
dentical to those previously obtained using counseling alone
s the primary mode of therapy (8), it may be inferred that
udrocortisone and salt plus counseling is no better than
ounseling alone. For the entire cohort, only 53% had no
igure 1. Symptom-free survival.Dashed line placebo; solid line salt
nd fludrocortisone.ecurrence of their symptoms after a positive tilt test. These aata are similar to those reported for the rate of recurrence
n open-label studies in children (3,4). In the study by Scott
t al. (4), there was no difference between fludrocortisone up
o 0.2 mg per day and atenolol up to a dose of 100 mg per
ay in preventing the recurrence of syncope. The recurrence
ate for their entire group using the standard we used in our
tudy, that is, any recurrence, was 52% (30 of 58 children).
oreover, the recurrence rate reported herein is in agree-
ent with the recurrence rate reported in our previous
pen-labeled study (52%) (9). The rate of recurrence re-
orted in the current study is also similar to the study in
hildren by Balaji et al. (3) (43%). In addition, randomized
lacebo-controlled trials in adults have produced similar
esults. For example, Madrid et al. (9) randomized patients
ith syncope regardless of the tilt test result to placebo
ersus atenolol and found no significant difference in the
ecurrence rate between groups. The initial studies in adults
omparing pacemakers with pharmacologic therapy for
ardioinhibitory syncope showed pacemakers to be more
ffective than medication (6). However, when patients with
pacemaker implanted were randomized to either placebo
inactive pacemaker) or active pacing therapy, there was no
ifference in the rate of recurrence between the groups (10).
he syncope recurrence rate was 42% for the placebo
acemaker group versus 33% for the active pacing group,
ith a recurrence rate after 6 months of follow-up of 38%
or the entire 100-patient cohort.
All our patients received counseling about syncope. Thus,
t was expected that any responses associated with the
ducation about syncope would have been similar in both
roups. Importantly, it has been shown that counseling
lone is not a very effective treatment for neurally mediated
yncope, because it provides relief of symptoms in only 35%
f patients (8). In addition, the placebo-counseling group
ad similar medication treatment as the fludrocortisone and
alt-counseling group except for the use of an active phar-
acologic agent. Thus, outcomes in the placebo group need
o be attributed not only to the effect of counseling but also
o the effect of a placebo.
The placebo effect had been attributed to manipulation of
he patient’s mechanisms of coping with illnesses and
esponding to medications or interventions with relief of
ymptoms. In an excellent review of the placebo effect,
tewart-Williams (11) discusses the theories put forth to
xplain the placebo effect. The results obtained in our
atients fit the expectancy theory, which espouses the
otion that with the explanation given to them regarding
he nature of their illness a medication given to them would
roduce the desired effect. This was starkly obvious in our
lacebo group patients who were symptom-free while on
herapy. In the classic conditioning theory, an event asso-
iated with an unrelated stimulus creates a positive response
nd an improvement in symptoms. The attention received
y the children during tilt testing, including intravenous
ccess, tilt, and provoking their symptoms, would create an
ssociation with previous events or visits to physicians for
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February 15, 2005:484–8 Fludrocortisone and Salt in Syncopether illnesses. These visits may have been associated with a
ositive response with relief of their symptoms. As a result,
hey perceive that all the work-up leading to their diagnosis
nd therapy would have to result in a similar improvement
n their symptoms, hence it did.
Stewart-Williams (11) also discussed the emotional
hange theory. This theory proposes that a reduction in the
nxiety experienced by the children and their family regard-
ng syncope would lead to relief of symptoms. Thus, the
nderstanding that syncope is a non–life-threatening con-
ition would alleviate the child’s anxiety and result in a
etter control of symptoms. This phenomenon may have
lso been operative in our patients with syncope. The
chematic processing mechanism of the placebo effect leads
o the perception of less severe symptoms after an interven-
ion, even though there was no obvious change. This
echanism may have been operative in our presyncope
atients who may have perceived an improvement in their
ymptoms while on therapy.
It is believed that salt and fludrocortisone prevent syncope
ecurrence by blunting the physiologic responses to the
pright position. Because of gravity, the upright position
educes venous return, and thus, decreases cardiac filling and
utput. Syncope is a result of the failure of the compensa-
ory mechanisms (including an increase in circulating cat-
cholamines and peripheral vasoconstriction). Fludrocorti-
one and salt expand the intravascular volume and may limit
he effects of gravity on venous return. The placebo effect is in
art related to the patient’s expectation of the medication,
onditioning on medical intervention, relief of anxiety by the
se of a medication, as well as, in part, to spontaneous
esolution of symptoms. Our data suggest that the mechanisms
hat create the placebo effect may play a role in modifying the
utonomic reflexes that lead to the syncopal event.
The dose of fludrocortisone used in this study was the
tandard dose used in adults and children. It has been shown
o be safe in large studies (3,4), and we have demonstrated
hat it is associated with minimal electrolyte abnormalities
12). Thus, we did not obtain any blood tests on our
atients. Somatic complaints such as fatigue, chest pain, and
ausea were reported more in children on salt and fludro-
ortisone. Overall, seven of the salt and fludrocortisone
roup children had reported some complaints compared
ith only two in the placebo group.
Limitations of the study include sample size, duration of
herapy, and dosage of active agent. Despite these limita-
ions, we have demonstrated a very significant placebo
ffect. The observations made in our study and by other
nvestigators raise the dilemma of determining the best
herapy for these patients. Our patients on placebo fared
etter than those on active therapy. This was an interesting
nd unexpected outcome. The question must be asked:
How can an inactive agent produce a better result than an
ctive agent?” The previously mentioned limitations may
ave been operative in producing this result. In addition, the
atural fluctuations and frequency of symptoms could haveffected outcome. Finally, there are a number of published
eports that address the issue of the character of the tablet in
reating the placebo effect (13). In our study, the active
gents were mere white tablets, whereas the placebos were a
reen capsule and an orange capsule. These capsules may
ave been perceived as a more effective medication. Con-
idering the results reported herein, our understanding of
he mechanism of syncope may need revision. The auto-
omic contribution to the syncopal episode may be consis-
ent from patient to patient. However, the trigger to the
utonomic response is probably quite variable. Whether
sychological or yet to be defined factors that trigger the
utonomic response are important in the pathophysiology of
yncope is unknown.
ONCLUSIONS
ecause others and we have shown a significant placebo
ffect with either pharmacologic or pacemaker intervention
n the treatment of autonomic mediated syncope, perhaps
urther investigation should focus on delineating the trig-
ering mechanisms of these troublesome events. If these
echanisms can be defined, a more rational and possibly
ore effective treatment plan can be devised.
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